Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline
- Raises additional 16M EUR led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors
- Funds will be used to further strengthen growing pipeline of first in class ADC assets, including lead asset targeting uPARAP
- Iyona Rajkomar, Managing Partner at Dawn Biopharma, joins Adcendo Board of Directors
Copenhagen, Denmark, May 29th, 2024 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a second Series A extension financing, raising a total of 98M EUR. This additional 16M EUR financing was led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors Novo Holdings, Ysios Capital, RA Capital Management, HealthCap, Gilde Healthcare and Pontifax Venture Capital. As part of the investment, Iyona Rajkomar, Managing Partner at Dawn Biopharma, will join the Adcendo Board of Directors.